Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lazard Life Sciences Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

St. Jude nabs ANS: Stock symbol ANSI pulled off the NASDAQ after St. Jude successfully acquires all outstanding shares of the neuromodulation firm, CFO John Heinmiller announces Nov. 30 at the Lazard Life Sciences Conference in New York. The firm made the $1.3 bil. acquisition offer in October to leverage its expertise in low-voltage cardiac stimulation with ANS' knowledge of spinal cord stimulation (1"The Gray Sheet" Oct. 24, 2005, p. 16). During the conference, Heinmiller said that St. Jude plans to heavily market its Atlas and Epic ICD lines to gain market share in Japan; the products launched in September. "That's about a $125 mil.-$150 mil. market that we can just begin to participate in," he said, noting that the firm's pacemakers enjoy a 25%-28% market share in Japan...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT022977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel